Matinas BioPharma Holdings (MTNB) Prepaid Assets (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Prepaid Assets of $367000.0 for Q1 2026, down 35.95% year-over-year from $573000.0 in Q1 2025, and up 1311.54% quarter-over-quarter from $26000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Prepaid Assets (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Prepaid Assets for 14 consecutive years, with $367000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets fell 35.95% year-over-year to $367000.0; the TTM figure through Mar 2026 stood at $367000.0 (down 35.95% YoY), while the FY2025 annual figure was $26000.0, down 96.24% from the prior year.
- Prepaid Assets improved to $367000.0 in Q1 2026 per MTNB's latest filing, from $26000.0 in the prior quarter.
- Across five years, Prepaid Assets topped out at $5.7 million in Q4 2022 and bottomed at $26000.0 in Q4 2025.
- Historically, Prepaid Assets has averaged $1.7 million across 5 years, with a median of $1.2 million in 2022.
- Annual changes were most pronounced in 2022 — Prepaid Assets soared 332.93% — and 2025, when it plunged 96.24%.
- Matinas BioPharma Holdings' Prepaid Assets stood at $5.7 million in 2022, then slumped by 69.63% to $1.7 million in 2023, then sank by 60.22% to $691000.0 in 2024, then slumped by 96.24% to $26000.0 in 2025, then jumped by 1311.54% to $367000.0 in 2026.
- Business Quant data shows MTNB's Prepaid Assets at $367000.0 in Q1 2026, $26000.0 in Q4 2025, and $168000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 332,000.00 |
| Mar 31, 2026 | 367,000.00 |
| Dec 31, 2025 | 26,000.00 |
| Sep 30, 2025 | 168,000.00 |
| Jun 30, 2025 | 693,000.00 |
| Mar 31, 2025 | 573,000.00 |
| Dec 31, 2024 | 691,000.00 |
| Sep 30, 2024 | 896,000.00 |
| Jun 30, 2024 | 922,000.00 |
| Mar 31, 2024 | 2.13 Mn |
| Dec 31, 2023 | 1.74 Mn |
| Sep 30, 2023 | 1.72 Mn |
| Jun 30, 2023 | 1.44 Mn |
| Mar 31, 2023 | 3.30 Mn |
| Dec 31, 2022 | 5.72 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 3.37 Mn |
| Mar 31, 2022 | 1.20 Mn |
| Dec 31, 2021 | 1.32 Mn |
| Sep 30, 2021 | 2.60 Mn |